IMNR - Immune Response Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Chris Wilkinson who wrote (128)	10/6/1997 11:57:00 AM
From: Mark B. Martell, CCM	of 1510

Yes Chris, You are right. I also received the information from IMNR regarding the mid year status report. I'm not sure what to make of this company still. We had an investor relations conference with no real news and the stock is now bleeding downward slightly. I was hoping for some early indications on the efficacy of Remune. We've received recently analysis from the aids community which talks about the virus as it adapts to the treatments (protease inhibitors, et al). If Remune could lengthen the success of these compounds by stimulating an autoimmune response, we could have a cash cow on our hands. I'm glad we are testing this compound with Merck's Crixivan, which, per a recent Wall Street Journal article, is experiencing some dramatic demand (above manufacturing capacity at Merck). This could be promising. Mark

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next